Impact of first-line cryoablation for atrial fibrillation on healthcare utilization, arrhythmia disease burden and efficacy outcomes: real-world evidence from the Cryo Global Registry.
Atrial fibrillation
Catheter ablation
Cryoballoon
First-line ablation
Registry
Journal
Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
ISSN: 1572-8595
Titre abrégé: J Interv Card Electrophysiol
Pays: Netherlands
ID NLM: 9708966
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
27
06
2022
accepted:
29
09
2022
medline:
4
4
2023
pubmed:
5
11
2022
entrez:
4
11
2022
Statut:
ppublish
Résumé
Cryoballoon ablation (CBA) is an effective first-line treatment for symptomatic atrial fibrillation (AF), as recently demonstrated by three randomized trials. This sub-analysis of the Cryo Global Registry aims to examine current clinical practices of first-line CBA. AF patients treated with first-line CBA were compared to CBA in antiarrhythmic drug (AAD)-refractory patients at 12 months. Efficacy was examined using time-to-first atrial arrhythmia recurrence following a 90-day blanking period. Healthcare utilization was evaluated by repeat ablations and hospitalizations. Disease burden was examined by assessing quality of life (QOL) and patients' reporting of symptoms. Of 1394 patients, 433 (31.1%) were treated with first-line CBA, which was more frequent in high-volume centers. Serious procedure-related adverse event rates were similar. Efficacy at 12 months was higher in the first-line group (87.8 vs. 81.6%, HR In this global real-world experience, first-line CBA in patients with symptomatic AF is effective, with a larger symptom reduction compared with CBA after AAD failure and without a difference in healthcare utilization at mid-term follow-up. https://clinicaltrials.gov/ct2/show/NCT02752737.
Sections du résumé
BACKGROUND
BACKGROUND
Cryoballoon ablation (CBA) is an effective first-line treatment for symptomatic atrial fibrillation (AF), as recently demonstrated by three randomized trials. This sub-analysis of the Cryo Global Registry aims to examine current clinical practices of first-line CBA.
METHODS
METHODS
AF patients treated with first-line CBA were compared to CBA in antiarrhythmic drug (AAD)-refractory patients at 12 months. Efficacy was examined using time-to-first atrial arrhythmia recurrence following a 90-day blanking period. Healthcare utilization was evaluated by repeat ablations and hospitalizations. Disease burden was examined by assessing quality of life (QOL) and patients' reporting of symptoms.
RESULTS
RESULTS
Of 1394 patients, 433 (31.1%) were treated with first-line CBA, which was more frequent in high-volume centers. Serious procedure-related adverse event rates were similar. Efficacy at 12 months was higher in the first-line group (87.8 vs. 81.6%, HR
CONCLUSIONS
CONCLUSIONS
In this global real-world experience, first-line CBA in patients with symptomatic AF is effective, with a larger symptom reduction compared with CBA after AAD failure and without a difference in healthcare utilization at mid-term follow-up.
CLINICAL TRIAL REGISTRATION
BACKGROUND
https://clinicaltrials.gov/ct2/show/NCT02752737.
Identifiants
pubmed: 36331681
doi: 10.1007/s10840-022-01388-6
pii: 10.1007/s10840-022-01388-6
doi:
Substances chimiques
Anti-Arrhythmia Agents
0
Banques de données
ClinicalTrials.gov
['NCT02752737']
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
711-722Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383:1305–16. https://doi.org/10.1056/NEJMoa2019422 .
doi: 10.1056/NEJMoa2019422
pubmed: 32865375
Zhang YY, Qiu C, Davis PJ, et al. Predictors of progression of recently diagnosed atrial fibrillation in REgistry on Cardiac Rhythm DisORDers Assessing the Control of Atrial Fibrillation (RecordAF)-United States cohort. Am J Cardiol. 2013;112:79–84. https://doi.org/10.1016/j.amjcard.2013.02.056 .
doi: 10.1016/j.amjcard.2013.02.056
pubmed: 23561591
Hindricks G, Potpara T, Dagres N, et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020;42:373–498.
doi: 10.1093/eurheartj/ehaa612
Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2018;20(1):e1–160. https://doi.org/10.1093/europace/eux274 .
doi: 10.1093/europace/eux274
pubmed: 29016840
Wazni OM, Dandamudi G, Sood N, et al. Cryoballoon ablation as initial therapy for atrial fibrillation. N Engl J Med. 2021;384:316–24. https://doi.org/10.1056/NEJMoa2029554 .
doi: 10.1056/NEJMoa2029554
pubmed: 33197158
Kuniss M, Pavlovic N, Velagic V, et al. Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation. EP Europace. 2021;23(7):1033–41. https://doi.org/10.1093/europace/euab029 .
doi: 10.1093/europace/euab029
Andrade JG, Wells GA, Deyell MW, et al. Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med. 2020;384:305–15. https://doi.org/10.1056/NEJMoa2029980 .
doi: 10.1056/NEJMoa2029980
pubmed: 33197159
Cosedis Nielsen J, Johannessen A, Raatikainen P, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med. 2012;367:1587–95. https://doi.org/10.1056/NEJMoa1113566 .
doi: 10.1056/NEJMoa1113566
pubmed: 23094720
Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA. 2014;311:692–700. https://doi.org/10.1001/jama.2014.467 .
doi: 10.1001/jama.2014.467
pubmed: 24549549
Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA. 2005;293(21):2634–40. https://doi.org/10.1001/jama.293.21.2634 .
doi: 10.1001/jama.293.21.2634
pubmed: 15928285
Chun KRJ, Okumura K, Scazzuso F, et al. Safety and efficacy of cryoballoon ablation for the treatment of paroxysmal and persistent AF in a real-world global setting: results from the Cryo AF Global Registry. J of Arrhythmia. 2021;37(2):356–67. https://doi.org/10.1002/joa3.12504 .
doi: 10.1002/joa3.12504
Kuck KH, Brugada J, Fürnkranz A, et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med. 2016;374(23):2235–45. https://doi.org/10.1056/NEJMoa1602014 .
doi: 10.1056/NEJMoa1602014
pubmed: 27042964
Kuck KH, Fürnkranz A, Chun KR, et al. Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial. Eur Heart J. 2016;37(38):2858–65. https://doi.org/10.1093/eurheartj/ehw285 .
doi: 10.1093/eurheartj/ehw285
pubmed: 27381589
pmcid: 5070448
Kuck KH, Albenque JP, Chun KJ, et al. Repeat ablation for atrial fibrillation recurrence post cryoballoon or radiofrequency ablation in the FIRE AND ICE Trial. Circ Arrhythm Electrophysiol. 2019;12(6):e007247. https://doi.org/10.1161/CIRCEP.119.007247 .
doi: 10.1161/CIRCEP.119.007247
pubmed: 31693319
Baysal E, Okşul M, Burak C, et al. Decreasing time between first diagnosis of paroxysmal atrial fibrillation and cryoballoon ablation positively affects long-term consequences. J Interv Card Electrophysiol. 2022. https://doi.org/10.1007/s10840-022-01167-3 .
doi: 10.1007/s10840-022-01167-3
pubmed: 36357697
Kuck K-H, Lebedev DS, Mikhaylov EN, et al. Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST). EP Europace. 2021;23(3):362–369a. https://doi.org/10.1093/europace/euaa298 .
doi: 10.1093/europace/euaa298
Bavishi AA, Kaplan RM, Peigh G, et al. Patient characteristics as predictors of recurrence of atrial fibrillation following cryoballoon ablation. Pacing Clin Electrophysiol. 2019;42(6):694–704. https://doi.org/10.1111/pace.13669 .
doi: 10.1111/pace.13669
pubmed: 30912155
pmcid: 7025864
Aksu T, Baysal E, Guler TE, Golcuk SE, Erden İ, Ozcan KS. Predictors of atrial fibrillation recurrence after cryoballoon ablation. J Blood Med. 2015;29(6):211–7. https://doi.org/10.2147/JBM.S81551 .
doi: 10.2147/JBM.S81551
Chew DS, Black-Maier E, Loring Z, et al. Diagnosis-to-ablation time and recurrence of atrial fibrillation following catheter ablation: a systematic review and meta-analysis of observational studies. Circ Arrhythm Electrophysiol. 2020;13(4):e008128. https://doi.org/10.1161/CIRCEP.119.008128 .
doi: 10.1161/CIRCEP.119.008128
pubmed: 32191539
pmcid: 7359927
Moltrasio M, Iacopino S, Arena G, et al. First-line therapy: insights from a real-world analysis of cryoablation in patients with atrial fibrillation. J Cardiovasc Med. 2021;22:000–000. https://doi.org/10.2459/JCM.0000000000001176 .
doi: 10.2459/JCM.0000000000001176
Straube F, Dorwarth U, Ammar-Busch S, et al. First-line catheter ablation of paroxysmal atrial fibrillation: outcome of radiofrequency vs. cryoballoon pulmonary vein isolation. Europace. 2016;18:368–75. https://doi.org/10.1093/europace/euv271 .
doi: 10.1093/europace/euv271
pubmed: 26504108
Akkaya E, Berkowitsch A, Zaltsberg S, et al. Second-generation cryoballoon ablation as a first-line treatment of symptomatic atrial fibrillation: two-year outcome and predictors of recurrence after a single procedure. Int J Cardiol. 2018;259:76–81. https://doi.org/10.1016/j.ijcard.2017.11.011 .
doi: 10.1016/j.ijcard.2017.11.011
pubmed: 29579615